Table 5.
Multivariable analysis of prognostic factors of 68 NPC patients with positive postoperative pathological results
| Variable | PFS | OS | DMFS | LRRFS | LRFS | RRFS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 0.948 (0.458–1.962) | 0.885 | 1.365 (0.501–3.719) | 0.543 | 0.505 (0.164–1.555) | 0.234 | 0.750 (0.336–1.676) | 0.483 | 0.662 (0.231–1.895) | 0.442 | 1.097 (0.412–2.917) | 0.853 |
| Sex | 0.866 (0.401–1.871) | 0.715 | 0.506 (0.160–1.600) | 0.246 | 0.652 (0.192–2.208) | 0.492 | 0.568 (0.248–1.302) | 0.182 | 0.595 (0.202–1.752) | 0.346 | 0.489 (0.176–1.360) | 0.171 |
| T stage | 2.733 (1.139–6.557) | 0.024 | 4.523 (1.240–16.501) | 0.022 | 11.418 (2.406–54.182) | 0.002 | 1.616 (0.633–4.126) | 0.315 | 1.473 (0.441–4.923) | 0.529 | 2.985 (0.900–9.894) | 0.074 |
| N stage | 2.070 (0.555–7.726) | 0.279 | 2.852 (0.564–14.409) | 0.205 | 8.385 (1.213–57.978) | 0.031 | 1.380 (0.339–5.617) | 0.653 | 2.054 (0.303–13.919) | 0.461 | 2.979 (0.528–16.798) | 0.216 |
| Clinical stage | 0.593 (0.240–1.463) | 0.256 | 1.183 (0.369–3.790) | 0.777 | 0.361 (0.086–1.515) | 0.164 | 0.696 (0.285–1.697) | 0.425 | 0.467 (0.132–1.651) | 0.237 | 0.621 (0.192–2.008) | 0.426 |
| EBV DNA before first treatment | 1.166 (0.553–2.459) | 0.687 | 0.812 (0.287–2.295) | 0.695 | 1.296 (0.287–0.423) | 0.650 | 1.762 (0.770–4.033) | 0.180 | 0.868 (0.300–2.510) | 0.793 | 3.631 (1.013–13.019) | 0.048 |
| Preoperative EBV DNA | 1.589 (0.768–3.290) | 0.212 | 3.501 (1.075–11.398) | 0.037 | 2.051 (0.688–6.119) | 0.197 | 1.575 (0.732–3.389) | 0.246 | 2.588 (0.926–7.234) | 0.070 | 1.827 (0.684–4.882) | 0.229 |
| Treatment for NPC | 1.341 (0.800–2.247) | 0.266 | 1.621 (0.684–3.845) | 0.273 | 3.367 (1.081–10.489) | 0.036 | 1.120 (0.657–1.910) | 0.677 | 0.840 (0.461–1.531) | 0.569 | 2.184 (0.874–5.459) | 0.095 |
NPC nasopharyngeal carcinoma, PFS progression-free survival, OS overall survival, DMFS distant metastasis-free survival, LRRFS locoregional relapse-free survival, LRFS local relapse-free survival, RRFS regional relapse-free survival, HR hazard ratio, CI confidence interval
All variables were transformed into categorical variables. HRs were calculated for age (≥ 45 vs. < 45 years), sex (male vs. female), T stage (3–4 vs. 1–2), N stage (3 vs. 1–2), clinical stage (IV vs. III vs. II), EBV DNA before first treatment (> 4000 vs. ≤ 4000 copies/mL), preoperative EBV DNA (> 0 vs. 0 copy/mL), and treatment for NPC (RT vs. CCRT vs. NAC + CCRT vs. CCRT + AC)